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Correspondence Renal Artery Stenosis AfterRenal Sympathetic DenervationTo the Editor: Renal sympathetic denervation (RDN) has been
dopted in a number of countries as an additional treatment option
o supplement antihypertensive therapy in patients with resistant
ypertension. Concerns have been raised with regard to the
ossible occurrence of renal artery stenosis (RAS). In the follow-
ng, we present a case of RAS as the consequence of RDN.
Baseline angiography demonstrated a right main and upper pole
ccessory renal artery (Fig. 1) and a single left renal artery without
ignificant stenoses. Six ablations were performed in each main renal
rtery, and 2 ablations were performed in the smaller right upper pole
ccessory renal artery. There were no procedural complications. After
months, due to recurrent hypertension, renal angiography was
erformed demonstrating an 80% ostial and 70% mid-segment right
ain renal artery stenosis and a mid 50% stenosis in the right upper
ole accessory renal artery (Fig. 1). There was no significant stenosis
n the left renal artery. The 2 (ostial and mid) right main renal artery
tenoses were successfully stented.
The merit of RDN to treat hypertension has been demonstrated
n 2 trials using one type of radiofrequency catheter, the same used
n the case described (1). The basis of this technology is an
ntended tissue injury caused by heat generated by radiofrequency
nergy. Injury is predominantly limited to the renal sympathetic
erve fibers that are more sensitive to heat than the remainder of
he surrounding tissue. Nevertheless, unintended tissue injury to
urrounding vascular structures causing edema and, perhaps, in-
ammation and fibrosis is conceivable. This might result in vessel
tenosis. Therefore, it is not surprising that pulmonary vein
tenoses have been described after pulmonary vein isolation with
adiofrequency energy (2). Human data characterizing the early
istological changes are not available, but radiofrequency applica-
ion to pulmonary veins in an animal model causes endothelial
enudation, organizing thrombus within a thickened intima,
isruption and thickening of the internal elastic lamina, and
ecrotic myocytes (3). Importantly, the energy used to achieve
ulmonary vein isolation is typically several magnitudes higher
han that used for RDN. Moreover, despite the use of higher
nergy levels, pulmonary vein stenosis after pulmonary vein isola-
ion is rare (1.5%) (2). Similar to changes observed after
ulmonary vein isolation, apart from the intended sympathetic
erve fibrosis, mild changes in other parts of the vessel wall after
adiofrequency denervation of the renal sympathetic nerves were
een in all treated arteries of an animal model at 6-month
ollow-up, including fibrosis of the deep media and underlying
dventitia as well as disruption of the external elastic lamina and
ntimal thickening (4). These changes were not accompanied by
ny significant angiographic changes. In all human studies thus far
erformed, focal luminal irregularities have been observed imme-
iately after the procedure and were attributed to vasospasm
nd/or edema. In a combination of patients from the proof-of-
rinciple Symplicity HTN-1 (Catheter-based Renal SympatheticDenervation for Resistant Hypertension) study and registry pa-
tients as well as patients from the Symplicity HTN-2 (Renal
Sympathetic Denervation in Patients with Treatment-Resistant
Hypertension) study, 202 underwent RDN. Twenty patients were
studied with surveillance angiography at 14 to 30 days, and 124
patients with magnetic resonance angiography, computed tomog-
raphy angiography, or duplex evaluation at 6-month follow-up
without evidence of renal artery stenosis with the exception of 2
cases of a stenosis reportedly remote from the ablation site in a
segment with pre-existent mild renal artery stenosis (5,6). More-
over, despite the widespread performance of this procedure, a RAS
directly related to the procedure has not yet been reported. This
might be due to the rare occurrence of this event or less-stringent
follow-up outside of trials or registries and frequent absence of
clinical symptoms related to it. A definitive statement cannot be
made. However, the most likely etiology of the RAS in our patient
was injury related to radiofrequency energy, perhaps the conse-
quence of tissue fibrosis in a more extensive manner than previ-
ously described in animal models. Other possibilities include
ablation catheter-induced mechanical injury and a de novo athero-
sclerotic lesion. However, both of these possibilities are less likely,
given the absence of dissection by angiography immediately after
ablation and mid location of one of the stenoses—a rather
uncommon finding with atherosclerotic RAS, because they are
located predominantly at the ostium. Renal sympathetic denerva-
tion remains a very promising tool for the treatment of resistant
hypertension. The incidence of RAS seems to be low. Neverthe-
less, given the small number of individuals with surveillance
imaging follow-up after RDN reported thus far and the frequently
clinically silent nature of RAS, it is conceivable that we have not
yet learned the true incidence and magnitude of this complication.
Taking into account the large number of patients with resistant
hypertension worldwide and, hence, expected number of patients
referred for and treated with RDN, it is very important to continue
close follow-up of patients treated with RDN. Therefore, partic-
ipation in registries with reliable imaging follow-up allowing
consistent reporting of this complication should be encouraged.
Further, device technology minimizing either mechanical or heat-
related vascular tissue injury needs to be explored, because—only if
the complications remain at an absolute minimum—will this
technology will prevail as an important adjunct to conventional
antihypertensive therapy.
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Figure 1 Angiographic Images
The right main renal artery and right upper pole accessory renal artery are illustrat
once again 5 months after renal sympathetic denervation (C and D, respectively).aper to disclose.EFERENCES
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